Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ICT-121 DC vaccine · 1 trial · 1 indication
To assess safety of the autologous ICT-121 DC vaccine the following will be monitored: Serious Adverse events, treatment emergent adverse events, treatment related toxicities
| Arm | Type | Description |
|---|---|---|
| ICT-121 DC vaccine | EXPERIMENTAL | Autologous dendritic cells pulsed with peptide antigens |
| Name | Type | Description |
|---|---|---|
| ICT-121 DC vaccine | BIOLOGICAL | autologous dendritic cells pulsed with peptide antigens |
Inclusion Criteria: 1. Any recurrence of a glioblastoma multiforme 2. ≥ 18 years of age 3. Human leukocyte antigen HLA A2 positive 4. Karnofsky Performance Score (KPS) of ≥ 70% 5. Baseline hematologic studies and chemistry profiles must meet the following criteria: * hemoglobin (Hgb) \> 9.9 g/d...
ICT-121 DC vaccine is an investigational dendritic cell vaccine being studied for the treatment of glioblastoma multiforme, a type of brain cancer. It is designed to stimulate the immune system to target tumor cells. The vaccine is currently in clinical development and is not yet approved by regulatory authorities.
ICT-121 DC vaccine is being developed by Precision BioSciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol DTIL. The company is conducting clinical research to evaluate the safety and efficacy of this investigational vaccine in patients with glioblastoma multiforme.
ICT-121 DC vaccine is in Phase 1 clinical development. A Phase 1 trial has been completed, which was designed to assess the safety and tolerability of the vaccine in patients with recurrent glioblastoma. The vaccine remains investigational and has not received approval from the U.S. Food and Drug Administration.
ICT-121 DC vaccine has been studied in one clinical trial, identified as NCT02049489, titled "A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma." This Phase 1 trial was conducted in the United States and enrolled 20 participants aged 18 years and older. The trial has been completed.
No, ICT-121 DC vaccine is not a monoclonal antibody. It is classified as a dendritic cell vaccine, a type of cellular immunotherapy. The vaccine is being developed for oncology, specifically for glioblastoma multiforme. Its mechanism involves using dendritic cells to present tumor antigens to the immune system.